Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hereditary Angioedema (HAE) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2017, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline landscape. Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cranding, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 4, 10 and 2 respectively. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology). - The pipeline guide reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development ActiveSite Pharmaceuticals Inc Adverum Biotechnologies Inc Arrowhead Pharmaceuticals Inc BioCryst Pharmaceuticals Inc Cevec Pharmaceuticals GmbH CSL Ltd Global Blood Therapeutics Inc iBio Inc Ionis Pharmaceuticals Inc Kalvista Pharmaceuticals Inc Pharming Group NV ProMetic Life Sciences Inc Shire Plc Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drug Profiles ADVM-053 - Drug Profile Product Description Mechanism Of Action R&D Progress AROF-12 - Drug Profile Product Description Mechanism Of Action R&D Progress ATN-035 - Drug Profile Product Description Mechanism Of Action R&D Progress ATN-249 - Drug Profile Product Description Mechanism Of Action R&D Progress BCX-7353 - Drug Profile Product Description Mechanism Of Action R&D Progress C1 esterase inhibitor (human) - Drug Profile Product Description Mechanism Of Action R&D Progress C1 esterase inhibitor (human) - Drug Profile Product Description Mechanism Of Action R&D Progress C1 esterase inhibitor (human) - Drug Profile Product Description Mechanism Of Action R&D Progress C1 esterase inhibitor (recombinant) - Drug Profile Product Description Mechanism Of Action R&D Progress C1 esterase inhibitor (recombinant) - Drug Profile Product Description Mechanism Of Action R&D Progress CSL-312 - Drug Profile Product Description Mechanism Of Action R&D Progress GBT-18713 - Drug Profile Product Description Mechanism Of Action R&D Progress icatibant acetate - Drug Profile Product Description Mechanism Of Action R&D Progress IONIS-PKKLRx - Drug Profile Product Description Mechanism Of Action R&D Progress IONIS-PKKRx - Drug Profile Product Description Mechanism Of Action R&D Progress KVD-818 - Drug Profile Product Description Mechanism Of Action R&D Progress lanadelumab - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile Product Description Mechanism Of Action R&D Progress SHP-623 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile Product Description Mechanism Of Action R&D Progress Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones Featured News & Press Releases May 25, 2017: BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial May 22, 2017: Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop May 18, 2017: Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial Apr 12, 2017: BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks Apr 04, 2017: New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients Mar 22, 2017: NEJM Publishes Pivotal Data on Preventing HAE Attacks Mar 16, 2017: Shire Receives European Approval for Label Extension of CINRYZE to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Pediatric Patients with HAE Mar 06, 2017: Attune Pharmaceuticals Announces Pre-Clinical Data for ATN-249, An Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at AAAAI Mar 01, 2017: Attune Pharmaceuticals Announces Late-Breaking Poster Presentation of ATN-249, an Oral Kallikrein Inhibitor for the Treatment of HAE Feb 27, 2017: BioCryst Reports Positive Interim Results from its APeX-1 Trial Feb 23, 2017: New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease Jan 16, 2017: European Commission amends Marketing Authorisation for RUCONEST to include self-administration Dec 15, 2016: CHMP Adopts Extension To Existing Therapeutic Indication For Cinryze Dec 01, 2016: CSL Commits to New Phase I Clinical Trials of CSL312 in Australia Nov 14, 2016: Pharming Announces the Presentation of the Results of the RUCONEST Phase II study for Prophylaxis of Hereditary Angioedema Attacks Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ActiveSite Pharmaceuticals Inc, H1 2017 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Adverum Biotechnologies Inc, H1 2017 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioCryst Pharmaceuticals Inc, H1 2017 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Cevec Pharmaceuticals GmbH, H1 2017 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Ltd, H1 2017 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Global Blood Therapeutics Inc, H1 2017 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by iBio Inc, H1 2017 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ionis Pharmaceuticals Inc, H1 2017 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Kalvista Pharmaceuticals Inc, H1 2017 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharming Group NV, H1 2017 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ProMetic Life Sciences Inc, H1 2017 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Shire Plc, H1 2017 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, H1 2017 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
